A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

NCT05279313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit/Hyperactivity Disorder

Interventions

DRUG: Centanafadine Hydrochloride

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.